SOURCE: Nutra Pharma Corporation

Nutra Pharma Corporation

June 23, 2010 09:03 ET

Nutra Pharma Begins Drug Registration Process in Central America for Its Nyloxin Pain Reliever

Nutra Pharma Has Begun the Drug Registration Process in Panama for Its Nyloxin Pain Reliever

CORAL SPRINGS, FL--(Marketwire - June 23, 2010) -  Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), announced today that it has begun the drug registration process in Panama for its Nyloxin pain reliever.

"As an important international business center, Panama offers us an opportunity to introduce our Nyloxin pain reliever in Central America," explained Rik J Deitsch, Chairman and CEO of Nutra Pharma. "We plan to move forward with this drug registration process in conjunction with finalizing our relationship with a prospective local distribution partner that has the resources and capabilities to successfully market and distribute Nyloxin throughout the country," he concluded.

Nyloxin, which was first introduced in November 2009 as a treatment for chronic pain, is currently available in the United States as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia, and as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis.

In the beginning of June, Nutra Pharma announced its partnership with the healthcare products distributor Henry Schein for distribution of its Nyloxin-branded pain relievers in the United States. Henry Schein, which ranks #339 on the Fortune 500 list, is the largest distributor of healthcare products and services to medical, dental, and veterinary office-based practitioners.

Additionally, the Company recently selected Grupo Farmacéutico de Tijuana (GFT) as its exclusive distributor for Nyloxin in Mexico. GFT specializes in the distribution of pharmaceutical products to large, national retailers and to over 3,000 pharmacies throughout Mexico.

About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases.

The company, through its subsidiaries, carries out basic drug discovery research and clinical development, and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process.

Currently, Nutra Pharma offers several drug products for sale for the treatment of pain: Cobroxin, the first over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain, and Nyloxin Rx, the only non-narcotic and non-addictive treatment for severe (Stage 3) pain. Both Cobroxin and Nyloxin were developed by Nutra Pharma's wholly-owned drug discovery subsidiary, ReceptoPharm.

In addition to manufacturing Cobroxin and Nyloxin, ReceptoPharm is also developing proprietary therapeutic protein products primarily for the prevention and treatment of viral and neurological diseases, including Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN), and Human Immunodeficiency Virus (HIV), and pain in humans. Outside of its role as the drug discovery arm for Nutra Pharma, ReceptoPharm provides contract research services through its ISO class 5 and GMP certified facilities.

The company's wholly-owned medical devices subsidiary, Designer Diagnostics, engages in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases, such as Nontuberculous Mycobacteria (NTM).

Nutra Pharma continues to identify intellectual property and companies in the biotechnology arena as potential acquisition candidates.

http://www.NutraPharma.com
http://www.Nyloxin.com

SEC Disclaimer
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. Beginning the drug registration process for Nyloxin in Panama should not be construed as an indication in any way whatsoever of the future value of the Company's common stock or its financial value. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

Contact Information

  • Contact:
    Nutra Pharma Corp.
    David Isserman
    877-895-5647
    Email Contact